We have vaccines. We have treatments. The question is whether we'll use them equitably.
On August 21st, the World Health Organization declared mpox a global health emergency, as a newly mutated variant — clade 1b — swept through the Democratic Republic of Congo and into thirteen African nations, killing at a rate the world had not seen from this virus before. Unlike the strains that circulated in wealthier nations, this variant spreads more readily, strikes more severely, and falls hardest on children in regions already hollowed out by war and poverty. The WHO, mindful of its slow response to COVID-19, chose to name the emergency early — before the fire crossed the ocean — leaving the world to reckon once again with the oldest question in public health: whether the tools we possess will reach the people who need them most.
- A mutated form of mpox is moving through central Africa with unsettling speed, spreading through casual contact and killing 3 to 5 percent of those infected in the Democratic Republic of Congo — a fatality rate that dwarfs the near-zero toll of the variant circulating elsewhere.
- Children and vulnerable populations in conflict-torn regions bear the heaviest burden, as overcrowding, malnutrition, and inadequate healthcare transform an outbreak into a cascading humanitarian crisis.
- The WHO declared a global health emergency before clade 1b spread significantly beyond Africa — a deliberate break from the delayed response that drew fierce criticism during COVID-19 — though only one confirmed case outside the continent has been recorded.
- Canadians face low immediate risk, but travelers to East Africa are advised to seek vaccination at least six weeks before departure, with the two-dose Imvamune course costing roughly $200 out of pocket for most.
- Canada holds a national stockpile of mpox vaccine with no announced plans to share it internationally, echoing the hoarding patterns that defined the early COVID-19 vaccine rollout and raising urgent questions about global equity.
On August 21st, the World Health Organization formally declared mpox a global health emergency — not because the virus itself was new, but because it had become something more dangerous. A variant called clade 1b, spreading rapidly through the Democratic Republic of Congo, had already reached thirteen African countries. It moves through casual contact, strikes harder than its predecessors, and kills between 3 and 5 percent of those it infects in the DRC. Children have been among the most vulnerable. By contrast, the clade 2 variant circulating in other parts of the world, including Canada, has caused virtually no deaths.
The conditions fueling the outbreak are as much political as biological. The DRC is a place where war, poverty, and inadequate housing create fertile ground for infectious disease. The WHO, having absorbed sharp criticism for its slow response to COVID-19, chose this time to act before the variant spread significantly beyond Africa — a decision that may prove prescient, or may be judged an overreaction, depending on what comes next.
For Canadians, the immediate risk is low. University students need not fear a repeat of COVID-era disruption. Travelers heading to East Africa, however, are advised to get vaccinated — the two-dose Imvamune course, spaced six weeks apart, costs roughly $200 for most people, though it remains free for high-risk groups such as men who have sex with men and sex workers. Appointments have grown scarce in cities like Toronto as demand rises.
Canada holds a stockpile of mpox vaccine but has announced no plans to share it with the countries where the outbreak is most severe — a pattern that recalls the excess-dose hoarding of the COVID-19 era. One complicating footnote: Canadians who received the smallpox vaccine before routine vaccination ended in 1972 retain some cross-immunity to mpox, though that protection belongs only to older generations.
Unlike COVID-19, mpox arrives in a world that already has vaccines and treatments. The deeper question — whether those tools will be deployed equitably, and whether the conditions that allow epidemics to take root in places like the DRC will finally receive sustained attention — remains, as ever, unanswered.
On August 21st, the World Health Organization made official what public health officials had been watching with growing alarm: mpox had crossed the threshold into a global emergency. The declaration came as a new variant of the virus, spreading rapidly through the Democratic Republic of Congo, had already reached thirteen African countries and showed signs of behaving differently—more contagious, more severe, more deadly—than the mpox strains the world had learned to manage over previous decades.
The virus itself is not new. Mpox causes lesions and flu-like symptoms, and in most cases remains mild enough that people recover without serious intervention. But the variant now circulating in central Africa, known as clade 1b, operates by different rules. It spreads through casual contact rather than requiring the skin-to-skin transmission that characterized earlier strains. Whether it travels through the air remains hotly debated among virologists, but the practical effect is clear: it moves faster, it hits harder, and it kills at a rate between 3 and 5 percent in the Democratic Republic of Congo. Children have been particularly vulnerable. The clade 2 variant, which has been spreading primarily among men who have sex with men in other parts of the world including Canada, has caused virtually no deaths by comparison.
Why did the WHO move to declare an emergency now, when mpox has existed for decades? The answer lies partly in what changed about the virus itself—the mutation that produced clade 1b appears to have made it genuinely more infectious and more virulent. But it also lies in where the outbreak is happening. The Democratic Republic of Congo is a place where war, poverty, malnutrition, and inadequate housing create the conditions in which infectious diseases explode. These are not new problems, but they are the soil in which epidemics grow. The WHO, having faced criticism for moving too slowly on COVID-19, chose this time to act early and cautiously, declaring the emergency before the new variant had spread significantly outside Africa.
For most people in Canada and other wealthy nations, the immediate risk remains low. Only one case of clade 1b has been confirmed outside of Africa. Young people heading to university need not fear the kind of disruption that COVID-19 imposed on their high school years. Those planning travel to East Africa, including Kenya where safaris are popular, should consider vaccination—the WHO recommends it, particularly for people in higher-risk categories. But there are no travel restrictions, no mandatory vaccine requirements. The vaccine itself, called Imvamune, costs about one hundred dollars per dose, and the full course requires two shots spaced six weeks apart. For high-risk groups like men who have sex with men and sex workers, the vaccine is available free, though demand has made appointments scarce in some cities like Toronto.
Canada possesses a stockpile of mpox vaccine but has announced no plans to share it with countries where the outbreak is most severe. This mirrors a pattern from COVID-19, when Canada held millions of excess doses while other nations went without. The Public Health Agency of Canada advises travelers to consult a health care provider or travel clinic at least six weeks before departure, but the practical reality is that most people will need to pay out of pocket for protection.
One historical note complicates the picture slightly: people who received the smallpox vaccine before Canada stopped routine vaccination in 1972 carry some cross-immunity to mpox. But that protection applies only to older generations. The resurgence of mpox has nothing to do with the time elapsed since smallpox vaccination ended. Rather, it reflects two distinct phenomena: the clade 2 outbreak stems from increased unprotected sex among men who have sex with men, a pattern also driving a concurrent surge in syphilis cases. The clade 1b outbreak in the Democratic Republic of Congo, by contrast, reflects a virus that has mutated into a more dangerous form, spreading in a region where the conditions for disease transmission are dire.
The WHO's early declaration of emergency may prove prescient or, as some critics suggest, an overreaction. What remains certain is that mpox, unlike COVID-19 when it emerged, is not a novel pathogen. We have vaccines. We have treatments. The question now is whether the world will deploy them equitably, and whether the conditions that allow infectious diseases to flourish in places like the Democratic Republic of Congo will finally receive the sustained attention they deserve.
Citas Notables
We don't know how easily the new strain can spread, but case numbers have not exploded the way they did in early COVID days— André Picard, health columnist
WHO seems to have learned lessons from COVID-19. This time around, it acted early and cautiously— André Picard
La Conversación del Hearth Otra perspectiva de la historia
Why did the WHO wait so long to declare this an emergency if the virus has been around for decades?
They didn't wait, actually—that's the point. With COVID, the WHO hesitated, and people criticized them for it. This time they moved early, before clade 1b had spread far outside Africa. The urgency comes from the variant itself, not the virus's age. This one spreads differently, kills at a higher rate, and seems to have mutated into something genuinely more dangerous.
So if Canada has vaccines, why not send them to the Congo where people are actually dying?
That's the uncomfortable question. Canada has a stockpile but says it needs to keep them in case mpox spreads here. It's the same thing that happened with COVID—we held onto millions of doses while other countries had none. There's no clear public explanation for why the risk to Canada justifies withholding vaccines from an active outbreak.
Is this going to be another pandemic that shuts everything down?
Almost certainly not. The case numbers haven't exploded the way COVID's did in early 2020. Only one case of the new variant has shown up outside Africa. Young people shouldn't expect their university years to be disrupted the way high school was. The virus is serious where it's spreading, but the conditions are very different.
What's the difference between the two variants people keep mentioning?
Clade 2 spreads mainly through sexual contact and causes virtually no deaths. Clade 1b spreads through casual contact, causes severe illness, and kills 3 to 5 percent of people it infects in the Congo. That's the one that triggered the emergency declaration.
If I'm vaccinated against smallpox, am I protected?
Only if you got that vaccine before 1972, when Canada stopped giving it routinely. If you have a scar on your upper arm from a smallpox shot, yes, you have some cross-immunity. But that's a shrinking population. Chickenpox won't help you—it's actually a different kind of virus entirely.
Why is the Congo hit so much harder than anywhere else?
The virus is more dangerous there, yes, but it's also spreading in a place where people are already vulnerable. War, poverty, malnutrition, poor housing—these aren't new problems, but they're the conditions where diseases spread fastest. The virus didn't create those conditions. It just found them.